Folger Nolan Fleming Douglas Capital Management Inc. Sells 1,414 Shares of Johnson & Johnson (NYSE:JNJ)

Folger Nolan Fleming Douglas Capital Management Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 106,726 shares of the company’s stock after selling 1,414 shares during the quarter. Johnson & Johnson makes up approximately 1.8% of Folger Nolan Fleming Douglas Capital Management Inc.’s portfolio, making the stock its 11th largest holding. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Johnson & Johnson were worth $16,728,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. McCarthy Asset Management Inc. raised its position in shares of Johnson & Johnson by 0.7% in the fourth quarter. McCarthy Asset Management Inc. now owns 14,502 shares of the company’s stock valued at $2,273,000 after purchasing an additional 103 shares during the period. Alliance Wealth Advisors LLC UT boosted its stake in Johnson & Johnson by 1.4% during the fourth quarter. Alliance Wealth Advisors LLC UT now owns 4,714 shares of the company’s stock worth $739,000 after buying an additional 64 shares in the last quarter. Schwarz Dygos Wheeler Investment Advisors LLC boosted its stake in Johnson & Johnson by 0.6% during the fourth quarter. Schwarz Dygos Wheeler Investment Advisors LLC now owns 14,085 shares of the company’s stock worth $2,208,000 after buying an additional 82 shares in the last quarter. Private Wealth Partners LLC boosted its stake in shares of Johnson & Johnson by 8.7% in the 4th quarter. Private Wealth Partners LLC now owns 74,330 shares of the company’s stock valued at $11,650,000 after purchasing an additional 5,930 shares in the last quarter. Finally, Addison Advisors LLC boosted its stake in shares of Johnson & Johnson by 5.9% in the 4th quarter. Addison Advisors LLC now owns 8,903 shares of the company’s stock valued at $1,395,000 after purchasing an additional 494 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now owns 141,416 shares of the company’s stock, valued at approximately $22,099,078.32. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on JNJ. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Monday, April 15th. Bank of America reduced their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Morgan Stanley cut their price target on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $175.86.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $149.92 on Friday. The company has a current ratio of 1.17, a quick ratio of 0.91 and a debt-to-equity ratio of 0.36. The business has a 50-day moving average of $154.44 and a 200-day moving average of $155.08. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm has a market capitalization of $361.27 billion, a P/E ratio of 9.35, a PEG ratio of 2.49 and a beta of 0.55.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business had revenue of $21.38 billion during the quarter, compared to analyst estimates of $21.39 billion. During the same period in the previous year, the firm earned $2.68 EPS. Johnson & Johnson’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a $1.24 dividend. The ex-dividend date of this dividend is Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.31%. Johnson & Johnson’s payout ratio is currently 29.68%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.